These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 16673210)

  • 1. Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals.
    Mueller A; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Dittrich R
    Horm Metab Res; 2006 Mar; 38(3):183-7. PubMed ID: 16673210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
    Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
    Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone.
    Mueller A; Dittrich R; Binder H; Kuehnel W; Maltaris T; Hoffmann I; Beckmann MW
    Eur J Endocrinol; 2005 Jul; 153(1):107-13. PubMed ID: 15994752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
    Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels.
    Bannink EM; van Sassen C; van Buuren S; de Jong FH; Lequin M; Mulder PG; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):265-73. PubMed ID: 19200215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women.
    Spinder T; Spijkstra JJ; Gooren LJ; Hompes PG; van Kessel H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):200-7. PubMed ID: 2491861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.
    Nuver J; Smit AJ; Wolffenbuttel BH; Sluiter WJ; Hoekstra HJ; Sleijfer DT; Gietema JA
    J Clin Oncol; 2005 Jun; 23(16):3718-25. PubMed ID: 15738540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist.
    Mueller A; Zollver H; Kronawitter D; Oppelt PG; Claassen T; Hoffmann I; Beckmann MW; Dittrich R
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):95-100. PubMed ID: 20625973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis.
    Sathyapalan T; González S; Atkin SL
    Climacteric; 2009 Oct; 12(5):427-30. PubMed ID: 19637056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes of serum testosterone-estradiol-binding globulin, follicular stimulating hormone, luteinizing hormone, estradiol, progesterone, and testosterone levels in women associated with aging].
    Kamatsuki S
    Igaku Kenkyu; 1982 Nov; 52(5):243-55. PubMed ID: 6821181
    [No Abstract]   [Full Text] [Related]  

  • 16. Short term changes in melatonin and cortisol serum levels after a single administration of estrogen to menopausal women.
    Kerdelhué B; Andrews MC; Zhao Y; Scholler R; Jones HW
    Neuro Endocrinol Lett; 2006 Oct; 27(5):659-64. PubMed ID: 17159819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testicular function in hyperthyroidism.
    Hudson RW; Edwards AL
    J Androl; 1992; 13(2):117-24. PubMed ID: 1597395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
    Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
    Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of circulating estradiol concentrations on gonadotropin secretion in young and old castrated male-to-female transsexuals.
    Ten Kulve JS; de Jong FH; de Ronde W
    Aging Male; 2011 Sep; 14(3):155-61. PubMed ID: 20828248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
    van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
    J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.